Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 21:14:1343999.
doi: 10.3389/fonc.2024.1343999. eCollection 2024.

BioPrev-C - development and validation of a contemporary prostate cancer risk calculator

Thomas Hermanns  1 , Marian S Wettstein  1 , Basil Kaufmann  1 , Noémie Lautenbach  1 , Ernest Kaufmann  1 , Karim Saba  1 , Florian A Schmid  1 , Andreas M Hötker  2 , Michael Müntener  3 , Martin Umbehr  3 , Cédric Poyet  1
Affiliations

BioPrev-C - development and validation of a contemporary prostate cancer risk calculator

Thomas Hermanns et al. Front Oncol. .

Abstract

Objectives: To develop a novel biopsy prostate cancer (PCa) prevention calculator (BioPrev-C) using data from a prospective cohort all undergoing mpMRI targeted and transperineal template saturation biopsy.

Materials and methods: Data of all men who underwent prostate biopsy in our academic tertiary care center between 11/2016 and 10/2019 was prospectively collected. We developed a clinical prediction model for the detection of high-grade PCa (Gleason score ≥7) based on a multivariable logistic regression model incorporating age, PSA, prostate volume, digital rectal examination, family history, previous negative biopsy, 5-alpha-reductase inhibitor use and MRI PI-RADS score. BioPrev-C performance was externally validated in another prospective Swiss cohort and compared with two other PCa risk-calculators (SWOP-RC and PBCG-RC).

Results: Of 391 men in the development cohort, 157 (40.2%) were diagnosed with high-grade PCa. Validation of the BioPrev C revealed good discrimination with an area under the curve for high-grade PCa of 0.88 (95% Confidence Interval 0.82-0.93), which was higher compared to the other two risk calculators (0.71 for PBCG and 0.84 for SWOP). The BioPrev-C revealed good calibration in the low-risk range (0 - 0.25) and moderate overestimation in the intermediate risk range (0.25 - 0.75). The PBCG-RC showed good calibration and the SWOP-RC constant underestimation of high-grade PCa over the whole prediction range. Decision curve analyses revealed a clinical net benefit for the BioPrev-C at a clinical meaningful threshold probability range (≥4%), whereas PBCG and SWOP calculators only showed clinical net benefit above a 30% threshold probability.

Conclusion: BiopPrev-C is a novel contemporary risk calculator for the prediction of high-grade PCa. External validation of the BioPrev-C revealed relevant clinical benefit, which was superior compared to other well-known risk calculators. The BioPrev-C has the potential to significantly and safely reduce the number of men who should undergo a prostate biopsy.

Keywords: biopsy; decision aids; nomograms; prostate cancer; prostate-specific antigen.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Calibration plots for the BiopPrev-C (Right), the PBCG RC (middle) and the SWOP RC (left) predicting high-grade prostate cancer. The x-axis shows predicted probabilities by the models and the y-axis shows the observed values.
Figure 3
Figure 3
Discrimination of the three risk calculators using a ROC analysis with corresponding AUC values for discriminating a biopsy harbouring high-grade prostate cancer.
Figure 4
Figure 4
Decision curve analysis for the prediction of high-grade prostate cancer upon biopsy using the either BiopPrev-C, the PBCG RC or the SWOP RC. Decision cures examine the theoretical relationship between the threshold probability of prostate cancer biopsy outcome and the releative value of false-positive and false-negative results to determine the value (net benefit) of a predictive model. The horizontal line along the x-axis assumes that no patient will have prostate cancer (i.e no patient should undergo a prostate biopsy) whereas the solid gray line assumes that all patients will have high-grade prostate cancer (i.e., all patients will need to undergo prostate biopsy).
See this image and copyright information in PMC

References

    1. Bandala-Jacques A, Castellanos Esquivel KD, Perez-Hurtado F, Hernandez-Silva C, Reynoso-Noveron N. Prostate cancer risk calculators for healthy populations: systematic review. JMIR Cancer (2021) 7:e30430. doi: 10.2196/30430 - DOI - PMC - PubMed
    1. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol (2010) 58:551–8. doi: 10.1016/j.eururo.2010.06.023 - DOI - PubMed
    1. Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol (2018) 74:197–203. doi: 10.1016/j.eururo.2018.05.003 - DOI - PMC - PubMed
    1. Mottet N, van den Bergh RCN, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer (2021). doi: 10.1016/j.eururo.2020.09.042 - DOI - PubMed
    1. Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N’Dow J, Sonksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021. Eur Urol (2021) 80:703–11. doi: 10.1016/j.eururo.2021.07.024 - DOI - PubMed